Who are Doravirine, Tenofovir, Lamivudine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atripla (r), Atripla or Stribild, TDF/3TC/EFV or DTG or NVP, tenofovir, lamivudine, efavirenz, Tenofovir, lamivudine and efavirenz, efavirenz + emtricitabina + tenofovir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doravirine-tenofovir-lamivudine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Doravirine, Tenofovir, Lamivudine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doravirine, Tenofovir, Lamivudine (Doravirine, Tenofovir, Lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NNRTI + NRTIs). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (NNRTI + NRTIs) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Doravirine, Tenofovir, Lamivudine (Doravirine, Tenofovir, Lamivudine) — Merck Sharp & Dohme LLC. This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Doravirine, Tenofovir, Lamivudine TARGET	Doravirine, Tenofovir, Lamivudine	Merck Sharp & Dohme LLC	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase, HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
tenofovir, lamivudine, efavirenz	tenofovir, lamivudine, efavirenz	Bamrasnaradura Infectious Diseases Institute	marketed	Antiretroviral combination therapy (NRTI/NtRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
efavirenz + emtricitabina + tenofovir	efavirenz + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NNRTI + NRTIs) class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Instituto Mexicano del Seguro Social · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doravirine, Tenofovir, Lamivudine — Competitive Intelligence Brief. https://druglandscape.com/ci/doravirine-tenofovir-lamivudine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab